Pharma bets a little-known type of cholesterol will underpin its next blockbuster heart drugs
Summary
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
Description
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source